1. To estimate effect size for producing clinical response (≥50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores) and remission (MADRS<12) in the ketamine group vs. the midazolam group at 14 and 42 days in both MDD and bipolar depression.